Fritz Sörgel
Research Subjects
Fritz Sörgel has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Cornelia Barbara Landersdorfer
Drug Delivery, Disposition, and Dynamics Theme, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Pde, Parkville, VIC, 3052, Australia
17 shared publications - Jurgen Bernd Bulitta
St. Jude Children’s Research Hospital
16 shared publications - Ulrike Holzgrabe
Institute of Pharmacy and Food Chemistry, Julius-Maximilians-University of Würzburg, Würzburg, Germany
15 shared publications Martina Kinzig
IBMP - Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany
10 shared publicationsMartina Kinzig-Schippers
Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg, Germany,1 University of Queensland, Brisbane, Australia,2 Institute of Pharmacy and Food Chemistry, University of Würzburg, Würzburg, Germany,3 Ordway Research Institute, Inc., Albany, New York 12208,4 Department of Pharmacology, University of Duisburg-Essen, Essen, Germany5
6 shared publicationsGeorge L. Drusano
Ordway Research Institute, Albany, NY 12208, USA
5 shared publications
Latest Publications
- Open Access
Caffeine, Paraxanthine, Theophylline, and Theobromine Content in Human Milk
This study aimed to assess the content of caffeine and its metabolites—paraxanthine, theophylline, and theobromine—in breast milk according to selected factors. Samples of human milk were collected from 100 women living in the east–northeast region of Poland. Information on the consumption of beverages and foods containing caffeine was collected using a 3 day food record. The determination of caffeine and its metabolite content was performed using liquid chromatography–mass spectrometry (LC–MS/MS). This study research showed that more caffeine was found in the milk of women living in cities, with secondary education, aged 34–43, and also in milk from the 3rd and 4th lactation periods (p ≤ 0.05). Factors such as place of residence, level of education, age, and stage of lactation influenced the nutritional choices of breastfeeding women, which had an impact on the level of caffeine and its metabolites in breast milk. A positive correlation was found between the consumption of caffeine with food and drinks and its level in human milk.
Open AccessCaffeine, Paraxanthine, Theophylline, and Theobromine Content in Human Milk
This study aimed to assess the content of caffeine and its metabolites—paraxanthine, theophylline, and theobromine—in breast milk according to selected factors. Samples of human milk were collected from 100 women living in the east–northeast region of Poland. Information on the consumption of beverages and foods containing caffeine was collected using a 3 day food record. The determination of caffeine and its metabolite content was performed using liquid chromatography–mass spectrometry (LC–MS/MS). This study research showed that more caffeine was found in the milk of women living in cities, with secondary education, aged 34–43, and also in milk from the 3rd and 4th lactation periods (p ≤ 0.05). Factors such as place of residence, level of education, age, and stage of lactation influenced the nutritional choices of breastfeeding women, which had an impact on the level of caffeine and its metabolites in breast milk. A positive correlation was found between the consumption of caffeine with food and drinks and its level in human milk.
- Open Access
- 10 July 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (7) , 323
Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
Quinolone antibiotics present an attractive oral treatment option in patients with cystic fibrosis (CF). Prior studies have reported comparable clearances and volumes of distribution in patients with CF and healthy volunteers for primarily renally cleared quinolones. We aimed to provide the first pharmacokinetic comparison for pefloxacin as a predominantly nonrenally cleared quinolone and its two metabolites between both subject groups. Eight patients with CF (fat-free mass [FFM]: 36.3 ± 6.9 kg, average ± SD) and ten healthy volunteers (FFM: 51.7 ± 9.9 kg) received 400 mg pefloxacin as a 30 min intravenous infusion and orally in a randomized, two-way crossover study. All plasma and urine data were simultaneously modelled. Bioavailability was complete in both subject groups. Pefloxacin excretion into urine was approximately 74% higher in patients with CF compared to that in healthy volunteers, whereas the urinary excretion of metabolites was only slightly higher in patients with CF. After accounting for body size and composition via allometric scaling by FFM, pharmacokinetic parameter estimates in patients with CF divided by those in healthy volunteers were 0.912 for total clearance, 0.861 for nonrenal clearance, 1.53 for renal clearance, and 0.916 for volume of distribution. Nonrenal clearance accounted for approximately 90% of total pefloxacin clearance. Overall, bioavailability and disposition were comparable between both subject groups.
- 10 July 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (7) , 323
Open AccessComparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
Quinolone antibiotics present an attractive oral treatment option in patients with cystic fibrosis (CF). Prior studies have reported comparable clearances and volumes of distribution in patients with CF and healthy volunteers for primarily renally cleared quinolones. We aimed to provide the first pharmacokinetic comparison for pefloxacin as a predominantly nonrenally cleared quinolone and its two metabolites between both subject groups. Eight patients with CF (fat-free mass [FFM]: 36.3 ± 6.9 kg, average ± SD) and ten healthy volunteers (FFM: 51.7 ± 9.9 kg) received 400 mg pefloxacin as a 30 min intravenous infusion and orally in a randomized, two-way crossover study. All plasma and urine data were simultaneously modelled. Bioavailability was complete in both subject groups. Pefloxacin excretion into urine was approximately 74% higher in patients with CF compared to that in healthy volunteers, whereas the urinary excretion of metabolites was only slightly higher in patients with CF. After accounting for body size and composition via allometric scaling by FFM, pharmacokinetic parameter estimates in patients with CF divided by those in healthy volunteers were 0.912 for total clearance, 0.861 for nonrenal clearance, 1.53 for renal clearance, and 0.916 for volume of distribution. Nonrenal clearance accounted for approximately 90% of total pefloxacin clearance. Overall, bioavailability and disposition were comparable between both subject groups.
- Open Access
- 18 June 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (6) , 286
Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding
The pharmacokinetics in patients with cystic fibrosis (CF) has long been thought to differ considerably from that in healthy volunteers. For highly protein bound β-lactams, profound pharmacokinetic differences were observed between comparatively morbid patients with CF and healthy volunteers. These differences could be explained by body weight and body composition for β-lactams with low protein binding. This study aimed to develop a novel population modeling approach to describe the pharmacokinetic differences between both subject groups by estimating protein binding. Eight patients with CF (lean body mass [LBM]: 39.8 ± 5.4kg) and six healthy volunteers (LBM: 53.1 ± 9.5kg) received 1027.5 mg cefotiam intravenously. Plasma concentrations and amounts in urine were simultaneously modelled. Unscaled total clearance and volume of distribution were 3% smaller in patients with CF compared to those in healthy volunteers. After allometric scaling by LBM to account for body size and composition, the remaining pharmacokinetic differences were explained by estimating the unbound fraction of cefotiam in plasma. The latter was fixed to 50% in male and estimated as 54.5% in female healthy volunteers as well as 56.3% in male and 74.4% in female patients with CF. This novel approach holds promise for characterizing the pharmacokinetics in special patient populations with altered protein binding.
- 18 June 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (6) , 286
Open AccessNovel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding
The pharmacokinetics in patients with cystic fibrosis (CF) has long been thought to differ considerably from that in healthy volunteers. For highly protein bound β-lactams, profound pharmacokinetic differences were observed between comparatively morbid patients with CF and healthy volunteers. These differences could be explained by body weight and body composition for β-lactams with low protein binding. This study aimed to develop a novel population modeling approach to describe the pharmacokinetic differences between both subject groups by estimating protein binding. Eight patients with CF (lean body mass [LBM]: 39.8 ± 5.4kg) and six healthy volunteers (LBM: 53.1 ± 9.5kg) received 1027.5 mg cefotiam intravenously. Plasma concentrations and amounts in urine were simultaneously modelled. Unscaled total clearance and volume of distribution were 3% smaller in patients with CF compared to those in healthy volunteers. After allometric scaling by LBM to account for body size and composition, the remaining pharmacokinetic differences were explained by estimating the unbound fraction of cefotiam in plasma. The latter was fixed to 50% in male and estimated as 54.5% in female healthy volunteers as well as 56.3% in male and 74.4% in female patients with CF. This novel approach holds promise for characterizing the pharmacokinetics in special patient populations with altered protein binding.
- 1 March 2018
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 56 (03) , 142-147
Azathioprine-induced reversible EBV-associated Hodgkin-like lymphoma after immunosuppressive therapy for autoimmune hepatitis
The use of immunosuppressive agents is associated with an increased risk of the development of certain types of malignancies, particularly lymphoma. Many of these lymphomas are associated with Epstein-Barr virus (EBV), which might be reactivated under immunosuppression. We present the case of a patient with an autoimmune hepatitis who developed EBV-associated Hodgkin-like lymphoma under immunosuppressive treatment with azathioprine. The tumor regressed spontaneously after withdrawal of azathioprine. The development of an EBV-associated Hodgkin-like lymphoma under this immunosuppressive therapy, and especially the regression of the lymphoma after cessation of azathioprine, confirms the relationship between this immunosuppressant, EBV-infection, and the development of Hodgkin-like lymphoma.
- 1 March 2018
- Published by Dustri-Verlag Dr. Karl Feistle in Int. Journal of Clinical Pharmacology and Therapeutics
- Vol. 56 (03) , 142-147
Azathioprine-induced reversible EBV-associated Hodgkin-like lymphoma after immunosuppressive therapy for autoimmune hepatitis
The use of immunosuppressive agents is associated with an increased risk of the development of certain types of malignancies, particularly lymphoma. Many of these lymphomas are associated with Epstein-Barr virus (EBV), which might be reactivated under immunosuppression. We present the case of a patient with an autoimmune hepatitis who developed EBV-associated Hodgkin-like lymphoma under immunosuppressive treatment with azathioprine. The tumor regressed spontaneously after withdrawal of azathioprine. The development of an EBV-associated Hodgkin-like lymphoma under this immunosuppressive therapy, and especially the regression of the lymphoma after cessation of azathioprine, confirms the relationship between this immunosuppressant, EBV-infection, and the development of Hodgkin-like lymphoma.
- 24 October 2016
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 112 (1) , 11-23
Pharmakokinetik und Pharmakodynamik von Antibiotika in der Intensivmedizin
Die optimale Dosierung von Antibiotika ist seit ihrer Einführung unklar geblieben. In den letzten 20 Jahren wurden 3 Pharmakokinetik(PK)-Pharmakodynamik(PD)-Indizes etabliert, die von Messungen der Konzentration des Antibiotikums im Plasma und der mittleren Hemmkonzentration (MHK) des die Infektion verursachenden Keims ausgehen. Für β‑Laktame gibt es Hinweise, dass deren Wirksamkeit von der Zeit abhängt, in der die Plasmakonzentration höher ist als die MHK. Bei Aminoglykosiden soll die Wirkung vom Verhältnis aus der maximal im Plasma erreichbaren Konzentration zur MHK abhängig sein. Für Vancomycin zeigen Studien, dass der Quotient aus der Fläche unter der Plasmaspiegelkurve (AUC) und der MHK mit der Wirksamkeit verbunden sein könnte. Für die Behandlung Schwerstkranker können diese PK-/PD-Parameter nur zur Orientierung dienen. Es fehlen nach wie vor Ergebnisse aus überzeugenden klinischen Studien an ausreichend großen Kollektiven von Schwerstkranken, die eine Vorhersage der Wirksamkeit erlauben. In der Praxis ist es deshalb schwer, ohne Orientierung an den Plasmaspiegeln eine rationale Therapie durchzuführen. Moderne Verfahren zur Analytik von allen derzeit verfügbaren Antibiotika im Plasma und die perfekte Logistik der Probenversendung erlauben es, auch kleineren Kliniken ohne hochspezialisiertes Massenspektroskopielabor ein therapeutisches Drugmonitoring (TDM) von Antibiotika durchzuführen. Vorschläge, wie Kliniken ein effizientes und den Betrieb einer Intensivstation nicht störendes TDM einführen können, werden gegeben. Auch zentrale TDM-Modelle, wie es etwa im Paul-Ehrlich-Antibiotika-Konzentrationsmessung(PEAK)-Projekt, das zu einer Vergleichbarkeit der Plasmakonzentrationen zwischen verschiedenen Zentren führen soll, entwickelt wird, werden vorgestellt. Optimized dosage regimens of antibiotics have remained obscure since their introduction. During the last two decades pharmacokinetic(PK)-pharmacodynamic(PD) relationships, originally established in animal experiments, have been increasingly used in patients. The action of betalactams is believed to be governed by the time the plasma concentration is above the minimum inhibitory concentration (MIC). Aminoglycosides act as planned when the peak concentration is a multiple of the MIC and vancomycin seems to work best when the area under the plasma vs. time curve (AUC) to MIC has a certain ratio. Clinicians should be aware that these relationships can only be an indication in which direction dosing should go. Larger studies with sufficiently high numbers of patients and particularly severely sick patients are needed to prove the concepts. In times where all antibiotics can be measured with new technologies, the introduction of therapeutic drug monitoring (TDM) is suggested for ICUs (Intensive Care Unit). The idea of a central lab for TDM of antibiotics such as PEAK (Paul Ehrlich Antibiotika Konzentrationsmessung) is supported.
- 24 October 2016
- Published by Springer Nature in Medizinische Klinik - Intensivmedizin und Notfallmedizin
- Vol. 112 (1) , 11-23
Pharmakokinetik und Pharmakodynamik von Antibiotika in der Intensivmedizin
Die optimale Dosierung von Antibiotika ist seit ihrer Einführung unklar geblieben. In den letzten 20 Jahren wurden 3 Pharmakokinetik(PK)-Pharmakodynamik(PD)-Indizes etabliert, die von Messungen der Konzentration des Antibiotikums im Plasma und der mittleren Hemmkonzentration (MHK) des die Infektion verursachenden Keims ausgehen. Für β‑Laktame gibt es Hinweise, dass deren Wirksamkeit von der Zeit abhängt, in der die Plasmakonzentration höher ist als die MHK. Bei Aminoglykosiden soll die Wirkung vom Verhältnis aus der maximal im Plasma erreichbaren Konzentration zur MHK abhängig sein. Für Vancomycin zeigen Studien, dass der Quotient aus der Fläche unter der Plasmaspiegelkurve (AUC) und der MHK mit der Wirksamkeit verbunden sein könnte. Für die Behandlung Schwerstkranker können diese PK-/PD-Parameter nur zur Orientierung dienen. Es fehlen nach wie vor Ergebnisse aus überzeugenden klinischen Studien an ausreichend großen Kollektiven von Schwerstkranken, die eine Vorhersage der Wirksamkeit erlauben. In der Praxis ist es deshalb schwer, ohne Orientierung an den Plasmaspiegeln eine rationale Therapie durchzuführen. Moderne Verfahren zur Analytik von allen derzeit verfügbaren Antibiotika im Plasma und die perfekte Logistik der Probenversendung erlauben es, auch kleineren Kliniken ohne hochspezialisiertes Massenspektroskopielabor ein therapeutisches Drugmonitoring (TDM) von Antibiotika durchzuführen. Vorschläge, wie Kliniken ein effizientes und den Betrieb einer Intensivstation nicht störendes TDM einführen können, werden gegeben. Auch zentrale TDM-Modelle, wie es etwa im Paul-Ehrlich-Antibiotika-Konzentrationsmessung(PEAK)-Projekt, das zu einer Vergleichbarkeit der Plasmakonzentrationen zwischen verschiedenen Zentren führen soll, entwickelt wird, werden vorgestellt. Optimized dosage regimens of antibiotics have remained obscure since their introduction. During the last two decades pharmacokinetic(PK)-pharmacodynamic(PD) relationships, originally established in animal experiments, have been increasingly used in patients. The action of betalactams is believed to be governed by the time the plasma concentration is above the minimum inhibitory concentration (MIC). Aminoglycosides act as planned when the peak concentration is a multiple of the MIC and vancomycin seems to work best when the area under the plasma vs. time curve (AUC) to MIC has a certain ratio. Clinicians should be aware that these relationships can only be an indication in which direction dosing should go. Larger studies with sufficiently high numbers of patients and particularly severely sick patients are needed to prove the concepts. In times where all antibiotics can be measured with new technologies, the introduction of therapeutic drug monitoring (TDM) is suggested for ICUs (Intensive Care Unit). The idea of a central lab for TDM of antibiotics such as PEAK (Paul Ehrlich Antibiotika Konzentrationsmessung) is supported.
- Open Access
- 14 March 2011
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 2927-2936
Comparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers
Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size. Twelve adult CF patients (median lean body mass [LBM] = 45.7 kg) and 12 healthy volunteers (LBM = 50.0 kg) received a single 10-min intravenous infusion of 2 g cefpirome. Plasma and urine concentrations were determined by high-performance liquid chromatography (HPLC). Population PK and Monte Carlo simulations were performed using NONMEM and S-ADAPT and a duration of an unbound plasma concentration above the MIC ≥ 65% of the dosing interval as a pharmacodynamic target. Unscaled clearances for CF patients were similar to those seen with healthy volunteers, and the volume of distribution was 6% lower for CF patients. Linear scaling of total clearance by WT resulted in clearance that was 20% higher (P ≤ 0.001 [nonparametric bootstrap]) in CF patients. Allometric scaling by LBM explained the differences between the two subject groups with respect to average clearance and volume of distribution and reduced the unexplained between-subject variability of renal and nonrenal clearance by 10 to 14%. For the CF patients, robust (>90%) probabilities of target attainment (PTA) were achieved by the administration of a standard dose of 2 g/70 kg WT every 12 h (Q12h) given as 30-min infusions for MICs ≤ 1.5 mg/liter. As alternative dosage regimens, a 5-h infusion of 1.33 g/70 kg WT Q8h achieved robust PTAs for MICs ≤ 8 to 12 mg/liter and a continuous infusion of 4 g/day for MICs ≤ 12 mg/liter. Prolonged infusion of cefpirome is expected to be superior to short-term infusions for MICs between 2 and 12 mg/liter.
- 14 March 2011
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (6) , 2927-2936
Open AccessComparable Population Pharmacokinetics and Pharmacodynamic Breakpoints of Cefpirome in Cystic Fibrosis Patients and Healthy Volunteers
Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size. Twelve adult CF patients (median lean body mass [LBM] = 45.7 kg) and 12 healthy volunteers (LBM = 50.0 kg) received a single 10-min intravenous infusion of 2 g cefpirome. Plasma and urine concentrations were determined by high-performance liquid chromatography (HPLC). Population PK and Monte Carlo simulations were performed using NONMEM and S-ADAPT and a duration of an unbound plasma concentration above the MIC ≥ 65% of the dosing interval as a pharmacodynamic target. Unscaled clearances for CF patients were similar to those seen with healthy volunteers, and the volume of distribution was 6% lower for CF patients. Linear scaling of total clearance by WT resulted in clearance that was 20% higher (P ≤ 0.001 [nonparametric bootstrap]) in CF patients. Allometric scaling by LBM explained the differences between the two subject groups with respect to average clearance and volume of distribution and reduced the unexplained between-subject variability of renal and nonrenal clearance by 10 to 14%. For the CF patients, robust (>90%) probabilities of target attainment (PTA) were achieved by the administration of a standard dose of 2 g/70 kg WT every 12 h (Q12h) given as 30-min infusions for MICs ≤ 1.5 mg/liter. As alternative dosage regimens, a 5-h infusion of 1.33 g/70 kg WT Q8h achieved robust PTAs for MICs ≤ 8 to 12 mg/liter and a continuous infusion of 4 g/day for MICs ≤ 12 mg/liter. Prolonged infusion of cefpirome is expected to be superior to short-term infusions for MICs between 2 and 12 mg/liter.
- Open Access
- 14 July 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (5) , 682-693
Nonlinear pharmacokinetics of piperacillin in healthy volunteers – implications for optimal dosage regimens
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Despite the clinical use of piperacillin for more than two decades, there are still contradictory reports whether or not the elimination of piperacillin is saturable at clinically relevant concentrations.• Two recent studies that applied population pharmacokinetic (PK) modelling found evidence for a saturable component of piperacillin elimination, whereas other published population PK analyses found non‐saturable elimination of piperacillin.• There is limited information on the between occasion variability of beta‐lactams (including piperacillin) and such data might be important to maximize the effectiveness by individualizing beta‐lactam dosage regimens. WHAT THIS STUDY ADDS • Saturable and non‐saturable components of renal elimination were identified for piperacillin and the unbound non‐saturable renal clearance of piperacillin was similar to the glomerular filtration rate.• Between occasion variability of clearance and volume of distribution at steady‐state of piperacillin was below 20% which indicated that the PK of piperacillin was predictable from one dosing interval to the next.• Monte Carlo simulation predicted 5 h infusions every 8 h and continuous infusion of piperacillin would be able to successfully treat infections by pathogens with a 2 to 4‐fold (5 to 8‐fold) higher MIC compared with 30 min infusions given every 6 h (every 8 h) at the same daily dose.AIMS: (i) To describe the first‐order and mixed‐order elimination pathways of piperacillin, (ii) to determine the between occasion variability (BOV) of pharmacokinetic parameters and (iii) to propose optimized dosage regimens.METHODS: We performed a five‐period replicate dose study in four healthy volunteers. Each subject received 4 g piperacillin as a single 5 min intravenous infusion in each study period. Drug analysis was performed by HPLC. We used NONMEM and S‐ADAPT for population pharmacokinetic analysis and Monte Carlo simulation to predict the probability of target attainment (PTA) with a target time of non‐protein bound concentration above MIC >50% of the dosing interval.RESULTS: A model with first‐order nonrenal elimination and parallel first‐order and mixed‐order renal elimination had the best predictive performance. For a 70 kg subject we estimated 4.40 l h−1 for nonrenal clearance, 5.70 l h−1 for first‐order renal clearance, 170 mg h−1 for Vmax, and 49.7 mg l−1 for Km for the mixed‐order renal elimination. The BOV was 39% for Vmax, 117% for Km, and 8.5% for total clearance. A 30 min infusion of 4 g every 6 h achieved robust (≥90%) PTAs for MICs ≤12 mg l−1. As an alternative mode of administration, a 5 h infusion of 6 g every 8 h achieved robust PTAs for MICs ≤48 mg l−1.CONCLUSIONS: Part of the renal elimination of piperacillin is saturable at clinically used doses. The BOV of total clearance and volume of distribution were low. Prolonged infusions achieved better PTAs compared with shorter infusions at similar daily doses. This benefit was most pronounced for MICs between 12 and 48 mg l−1.
- 14 July 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 70 (5) , 682-693
Open AccessNonlinear pharmacokinetics of piperacillin in healthy volunteers – implications for optimal dosage regimens
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Despite the clinical use of piperacillin for more than two decades, there are still contradictory reports whether or not the elimination of piperacillin is saturable at clinically relevant concentrations.• Two recent studies that applied population pharmacokinetic (PK) modelling found evidence for a saturable component of piperacillin elimination, whereas other published population PK analyses found non‐saturable elimination of piperacillin.• There is limited information on the between occasion variability of beta‐lactams (including piperacillin) and such data might be important to maximize the effectiveness by individualizing beta‐lactam dosage regimens. WHAT THIS STUDY ADDS • Saturable and non‐saturable components of renal elimination were identified for piperacillin and the unbound non‐saturable renal clearance of piperacillin was similar to the glomerular filtration rate.• Between occasion variability of clearance and volume of distribution at steady‐state of piperacillin was below 20% which indicated that the PK of piperacillin was predictable from one dosing interval to the next.• Monte Carlo simulation predicted 5 h infusions every 8 h and continuous infusion of piperacillin would be able to successfully treat infections by pathogens with a 2 to 4‐fold (5 to 8‐fold) higher MIC compared with 30 min infusions given every 6 h (every 8 h) at the same daily dose.AIMS: (i) To describe the first‐order and mixed‐order elimination pathways of piperacillin, (ii) to determine the between occasion variability (BOV) of pharmacokinetic parameters and (iii) to propose optimized dosage regimens.METHODS: We performed a five‐period replicate dose study in four healthy volunteers. Each subject received 4 g piperacillin as a single 5 min intravenous infusion in each study period. Drug analysis was performed by HPLC. We used NONMEM and S‐ADAPT for population pharmacokinetic analysis and Monte Carlo simulation to predict the probability of target attainment (PTA) with a target time of non‐protein bound concentration above MIC >50% of the dosing interval.RESULTS: A model with first‐order nonrenal elimination and parallel first‐order and mixed‐order renal elimination had the best predictive performance. For a 70 kg subject we estimated 4.40 l h−1 for nonrenal clearance, 5.70 l h−1 for first‐order renal clearance, 170 mg h−1 for Vmax, and 49.7 mg l−1 for Km for the mixed‐order renal elimination. The BOV was 39% for Vmax, 117% for Km, and 8.5% for total clearance. A 30 min infusion of 4 g every 6 h achieved robust (≥90%) PTAs for MICs ≤12 mg l−1. As an alternative mode of administration, a 5 h infusion of 6 g every 8 h achieved robust PTAs for MICs ≤48 mg l−1.CONCLUSIONS: Part of the renal elimination of piperacillin is saturable at clinically used doses. The BOV of total clearance and volume of distribution were low. Prolonged infusions achieved better PTAs compared with shorter infusions at similar daily doses. This benefit was most pronounced for MICs between 12 and 48 mg l−1.
- 21 January 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 69 (2) , 167-178
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Probenecid inhibits the active transport of both anionic and cationic drug molecules at various sites in the body.• Probenecid has been reported to decrease the elimination of several quinolones.• We are not aware of any reports where a mechanism‐based model for the interaction of quinolones and probenecid in humans or animals has been developed.WHAT THIS STUDY ADDS• Pharmacokinetic modelling indicates competitive inhibition of the renal tubular secretion of ciprofloxacin and its metabolite M1 by probenecid.• The affinity for the renal transporter was 4.4 times higher for ciprofloxacin and 3.6 times higher for M1 compared with probenecid, based on molar concentrations.• Probenecid did not affect volume of distribution of ciprofloxacin or M1, nonrenal clearance or intercompartmental clearance of ciprofloxacin.AIMS: Probenecid influences transport processes of drugs at several sites in the body and decreases elimination of several quinolones. We sought to explore extent, time course, and mechanism of the interaction between ciprofloxacin and probenecid at renal and nonrenal sites.METHODS: A randomized, two‐way crossover study was conducted in 12 healthy volunteers (in part previously published Clin Pharmacol Ther 1995; 58: 532–41). Subjects received 200 mg ciprofloxacin as 30‐min intravenous infusion without and with 3 g probenecid divided into five oral doses. Drug concentrations were analysed by liquid chromatography–tandem mass spectrometry and high‐performance liquid chromatography. Ciprofloxacin and its 2‐aminoethylamino‐metabolite (M1) in plasma and urine with and without probenecid were modelled simultaneously with WinNonlin®.RESULTS: Data are ratio of geometric means (90% confidence intervals). Addition of probenecid reduced the median renal clearance from 23.8 to 8.25 l h−1[65% reduction (59, 71),P < 0.01] for ciprofloxacin and from 20.5 to 8.26 l h−1(66% reduction (57, 73),P < 0.01] for M1 (estimated by modelling). Probenecid reduced ciprofloxacin nonrenal clearance by 8% (1, 14) (P < 0.08). Pharmacokinetic modelling indicated competitive inhibition of the renal tubular secretion of ciprofloxacin and M1 by probenecid. The affinity for the renal transporter was 4.4 times higher for ciprofloxacin and 3.6 times higher for M1 than for probenecid, based on the molar ratio. Probenecid did not affect volume of distribution of ciprofloxacin or M1, nonrenal clearance or intercompartmental clearance of ciprofloxacin.CONCLUSIONS: Probenecid inhibited the renal tubular secretion of ciprofloxacin and M1, probably by a competitive mechanism and due to reaching >100‐fold higher plasma concentrations. Formation of M1, nonrenal clearance and distribution of ciprofloxacin were not affected.
- 21 January 2010
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 69 (2) , 167-178
Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Probenecid inhibits the active transport of both anionic and cationic drug molecules at various sites in the body.• Probenecid has been reported to decrease the elimination of several quinolones.• We are not aware of any reports where a mechanism‐based model for the interaction of quinolones and probenecid in humans or animals has been developed.WHAT THIS STUDY ADDS• Pharmacokinetic modelling indicates competitive inhibition of the renal tubular secretion of ciprofloxacin and its metabolite M1 by probenecid.• The affinity for the renal transporter was 4.4 times higher for ciprofloxacin and 3.6 times higher for M1 compared with probenecid, based on molar concentrations.• Probenecid did not affect volume of distribution of ciprofloxacin or M1, nonrenal clearance or intercompartmental clearance of ciprofloxacin.AIMS: Probenecid influences transport processes of drugs at several sites in the body and decreases elimination of several quinolones. We sought to explore extent, time course, and mechanism of the interaction between ciprofloxacin and probenecid at renal and nonrenal sites.METHODS: A randomized, two‐way crossover study was conducted in 12 healthy volunteers (in part previously published Clin Pharmacol Ther 1995; 58: 532–41). Subjects received 200 mg ciprofloxacin as 30‐min intravenous infusion without and with 3 g probenecid divided into five oral doses. Drug concentrations were analysed by liquid chromatography–tandem mass spectrometry and high‐performance liquid chromatography. Ciprofloxacin and its 2‐aminoethylamino‐metabolite (M1) in plasma and urine with and without probenecid were modelled simultaneously with WinNonlin®.RESULTS: Data are ratio of geometric means (90% confidence intervals). Addition of probenecid reduced the median renal clearance from 23.8 to 8.25 l h−1[65% reduction (59, 71),P < 0.01] for ciprofloxacin and from 20.5 to 8.26 l h−1(66% reduction (57, 73),P < 0.01] for M1 (estimated by modelling). Probenecid reduced ciprofloxacin nonrenal clearance by 8% (1, 14) (P < 0.08). Pharmacokinetic modelling indicated competitive inhibition of the renal tubular secretion of ciprofloxacin and M1 by probenecid. The affinity for the renal transporter was 4.4 times higher for ciprofloxacin and 3.6 times higher for M1 than for probenecid, based on the molar ratio. Probenecid did not affect volume of distribution of ciprofloxacin or M1, nonrenal clearance or intercompartmental clearance of ciprofloxacin.CONCLUSIONS: Probenecid inhibited the renal tubular secretion of ciprofloxacin and M1, probably by a competitive mechanism and due to reaching >100‐fold higher plasma concentrations. Formation of M1, nonrenal clearance and distribution of ciprofloxacin were not affected.
- 31 October 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 65 (2) , 130-141
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers
- 31 October 2009
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 65 (2) , 130-141
Comparison of the pharmacokinetics and pharmacodynamic profile of carumonam in cystic fibrosis patients and healthy volunteers